ReviewEuropean journal of pediatrics2014
Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
Review in European journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Association between blood cell count inflammatory biomarkers and non-alcoholic fatty liver disease: A systematic review and meta-analysis.Endocrine · 2026Pooled it
- Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016Pooled it
- Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD.Nutrients · 2014Trial
- Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease: From Dysbiosis to Metagenomic Insights and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- AI-powered ultrasound radiofrequency analysis for non-invasive pediatric liver fat quantification.Scientific reports · 2026Article
- Obesity, Metabolic Syndrome and MASLD in Children: Inflammation as the Missing Link-A Short Narrative Review.Life (Basel, Switzerland) · 2026Review
- Diagnosis and Management of Pediatric Non-Alcoholic Fatty Liver Disease: An Overview.Metabolites · 2025Review
- Maternal, fetal, and neonatal toxicity and potency estimates of perfluorohexane sulfonate (PFHxS) from oral maternal exposure in the Sprague-Dawley rat.Toxicology · 2025Article
- Gaps and challenges in the management of pediatric steatotic liver diseases: a narrative review.World journal of pediatrics : WJP · 2025Review
- Longitudinal Links between Changes in Body Composition and Liver Disease Severity in Children and Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease.The Journal of pediatrics · 2025Article
- Hepatocyte-specific angiotensinogen deficiency inhibits Western diet-induced liver steatosis with suppression of cell division in mice.Global translational medicine · 2025Article
- Genome-Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease.BMC pediatrics · 2024Article
- Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver DiseaseJournal of clinical research in pediatric endocrinology · 2024Article
- Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity; Patient Characteristics and Association with Leptin-A Cross-Sectional Overview of Baseline Data from a RCT.Children (Basel, Switzerland) · 2024Article
- The relationship between the systemic immune inflammation index and the nonalcoholic fatty liver disease in American adolescents.BMC gastroenterology · 2024Article
- Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics.Hepatology communications · 2024Article
- Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease.Frontiers in medicine · 2024Review
- Irregular meal pattern and later sleep midpoint are associated with increased BMIFrontiers in pediatrics · 2024Article
- Case report: Pediatric hepatopulmonary syndrome despite strict weight control after craniopharyngioma surgery.Frontiers in endocrinology · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledNon-alcoholic fatty liver disease (NAFLD) is a multifactorial condition that encompasses a wide spectrum of liver abnormalities ranging from simple liver steatosis to steatohepatitis (non-alcoholic steatohepatitis), which may be associated with fibrosis and progress to cirrhosis and end-stage liver disease. NAFLD has recently become the most common cause of chronic liver disease in children and adolescents. NAFLD prevalence, alongside obesity, continues to increase among pediatric patients. Obesity is believed to represent a major risk factor for NAFLD, which is considered to be the liver presentation of the metabolic syndrome. Although the pathogenesis of NAFLD is not fully understood, the notion that multiple factors affect disease development and progression is widely accepted. Both genetic background and environmental factors contribute to NAFLD development. A more complete understanding of the pathogenesis may aid in developing non-invasive diagnostic tools and identifying new therapeutic targets. Liver biopsy currently remains the gold standard for NAFLD diagnosis and staging. Although lifestyle and diet modifications are key in NAFLD treatment, the development of new pharmacological therapies is crucial for patients who are unresponsive to first-line therapy.
conclusionPediatric NAFLD is an increasing public health issue that remains underdiagnosed. A large-scale screening in the high-risk population, especially among the overweight pediatric patients, should be considered, including measurement of serum transaminases and liver ultrasound. It is crucial to treat this condition as soon as possible in order to avoid the progression to end-stage liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.